Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma

Part of paid clinical trials in Seattle, Washington.

Sponsor
Swedish Medical Center
Study ID
NCT05380349
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Newly Diagnosed Glioblastoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • combinations of up to 3 FDA approved drugs from a panel of compounds — DRUG
    personalized drug combinations

Study Details

Proposed treatment of subjects with newly diagnosed glioblastoma with novel personalized drug regimens identified to be effective in vitro using cancer stem cells derived from their individual tumors, alongside standard of care radiation and TMZ.

Key Dates

Start date
Apr 19, 2024
Status verified
May 2025
Primary completion
Dec 31, 2026
Completion
Dec 31, 2027

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Personalized Combination Drug Therapy for Cancer Stem Cells
    Administer combinations of up to 3 FDA approved drugs from a panel of compounds selected based on high throughput screening

Primary Outcome Measure

determine safety of CSC/HTS-based combination drug therapy [ Time Frame: From date of first dose of investigational drug regimen until date of first documented progression or death from any cause, whichever came first, assessed up to 24 months. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Swedish Medical CenterSeattleWashington98122
Nathan Hansen
[email protected]
206-320-3542

Find similar trials in Seattle, WA

By research site
Swedish Medical Center· Seattle, WA

Related Studies